- Abstract:
-
An effective therapeutic vaccine for the treatment of chronic hepatitis C virus (HCV) infection, as an adjunct to newly developed directly-acting antivirals (DAA), or for the prevention of reinfection would significantly reduce the global burden of disease associated with chronic HCV infection.
Expand abstract
A recombinant chimpanzee adenoviral (ChAd3) vector and a modified vaccinia Ankara (MVA), encoding the non-structural proteins of HCV (NSmut), used in a heterologous prime/boost regimen induc... - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Publisher's version
- Publisher:
- MDPI Publisher's website
- Journal:
- Vaccines Journal website
- Publication date:
- 2016-08-02
- DOI:
- ISSN:
-
2076-393X
- URN:
-
uuid:5281d872-bdf3-44e4-baf0-c5f54c9e842c
- Source identifiers:
-
634778
- Local pid:
- pubs:634778
- Copyright holder:
- Swadling et al.
- Copyright date:
- 2016
- Notes:
- © 2016 by the author; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license.
Journal article
Highly immunogenic virally vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection
Actions
Authors
Funding
Wellcome Trust
More from this funder
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record